MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/00002030-199818000-00013

Медицинская библиотека · AIDS (London, England) · 1998

A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. AIDS Clinical Trials Group Protocol 135 Study Team.

Parenti D M, Williams P L, Hafner R, Jacobs M R, Hojczyk P, Hooton T M, Barber T W, Simpson G, van der Horst C, Currier J, Powderly W G, Limjoco M, Ellner J J

Клиническое исследованиеКлиническое исследование II фазыКлиническое исследование III фазыСравнительное исследованиеСтатьяРандомизированное исследованиеПоддержка службы здравоохранения СШАПеревод в очереди

Аннотация

OBJECTIVE

To determine the clinical and microbiologic benefit of adding amikacin to a four-drug oral regimen for treatment of disseminated Mycobacterium avium infection in HIV-infected patients.

DESIGN

A randomized, open-labeled, comparative trial.

SETTING

Outpatient clinics.

PATIENTS: Seventy-four patients with HIV and symptomatic bacteremic M. avium infection.

INTERVENTIONS: Rifampin 10 mg/kg daily, ciprofloxacin 500 mg twice daily, clofazimine 100 mg every day, and ethambutol 15 mg/kg orally daily for 24 weeks, with or without amikacin 10 mg/kg intravenously or intramuscularly 5 days weekly for the first 4 weeks.

MAIN OUTCOME MEASURE: Clinical and microbiologic response at 4 weeks; quantitative level of bacteremia with M. avium.

RESULTS

No difference in clinical response was noted with the addition of amikacin to the four-drug oral regimen, and only 25% in either group had a complete or partial response at 4 weeks. A comparable quantitative decrease in bacteremia was noted in both treatment groups, with 16% of patients being culture-negative at 4 weeks and 38% at 12 weeks. Toxicities were mainly gastrointestinal. Amikacin was well tolerated. Median survival was 30 weeks in both groups.

CONCLUSIONS

The addition of amikacin to a four-drug oral regimen of rifampin, ciprofloxacin, clofazimine, and ethambutol did not provide clinical or microbiologic benefit.

Для цитирования: Parenti D M, Williams P L, Hafner R, Jacobs M R, Hojczyk P, Hooton T M, Barber T W, Simpson G, van der Horst C, Currier J, Powderly W G, Limjoco M, Ellner J J. A phase II/III trial of antimicrobial therapy with or without amikacin in the treatment of disseminated Mycobacterium avium infection in HIV-infected individuals. AIDS Clinical Trials Group Protocol 135 Study Team.. AIDS (London, England). 1998. DOI: 10.1097/00002030-199818000-00013.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.